247 related articles for article (PubMed ID: 25519702)
21. Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
Baker CH; Trevino JG; Summy JM; Zhang F; Caron A; Nesbit M; Gallick GE; Fidler IJ
Int J Oncol; 2006 Jul; 29(1):125-38. PubMed ID: 16773192
[TBL] [Abstract][Full Text] [Related]
22. YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models.
Xu Y; Lin H; Meng N; Lu W; Li G; Han Y; Dai X; Xia Y; Song X; Yang S; Wei Y; Yu L; Zhao Y
Br J Pharmacol; 2013 Aug; 169(8):1766-80. PubMed ID: 23594209
[TBL] [Abstract][Full Text] [Related]
23. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial.
Cardin DB; Goff LW; Chan E; Whisenant JG; Dan Ayers G; Takebe N; Arlinghaus LR; Yankeelov TE; Berlin J; Merchant N
Invest New Drugs; 2018 Jun; 36(3):442-450. PubMed ID: 28990119
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
25. HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway.
Yao Y; Zhou L; Liao W; Chen H; Du Z; Shao C; Wang P; Ding K
Carbohydr Polym; 2019 Jan; 204():111-123. PubMed ID: 30366522
[TBL] [Abstract][Full Text] [Related]
26. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
27. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
28. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
[TBL] [Abstract][Full Text] [Related]
29. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
30. Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation.
Jang SI; Fang S; Baek YY; Lee DH; Na K; Lee SY; Lee DK
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111094
[TBL] [Abstract][Full Text] [Related]
31. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
[TBL] [Abstract][Full Text] [Related]
32. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
Nautiyal J; Majumder P; Patel BB; Lee FY; Majumdar AP
Cancer Lett; 2009 Oct; 283(2):143-51. PubMed ID: 19398150
[TBL] [Abstract][Full Text] [Related]
33. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
[TBL] [Abstract][Full Text] [Related]
34. Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR.
Kamiyama H; Kakeya H; Usui T; Nishikawa K; Shoji M; Hayashi Y; Osada H
Oncol Res; 2008; 17(1):11-21. PubMed ID: 18488711
[TBL] [Abstract][Full Text] [Related]
35. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
36. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
[TBL] [Abstract][Full Text] [Related]
37. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
Solorzano CC; Baker CH; Tsan R; Traxler P; Cohen P; Buchdunger E; Killion JJ; Fidler IJ
Clin Cancer Res; 2001 Aug; 7(8):2563-72. PubMed ID: 11489840
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
39. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.
Büchler P; Reber HA; Roth MM; Shiroishi M; Friess H; Hines OJ
Neoplasia; 2007 Feb; 9(2):119-27. PubMed ID: 17356708
[TBL] [Abstract][Full Text] [Related]
40. Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway.
Zhang B; Huang H; Xie J; Xu C; Chen M; Wang C; Yang A; Yin Q
Oncol Rep; 2012 Mar; 27(3):891-7. PubMed ID: 22139427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]